Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

NCT04322318 : Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Systemic<br/>Therapy TrialTypeSystemic
Therapy Trial

TwoPhase Two

<30Age Under 30

Urinary System<br/>CancersCancer LocationUrinary System
Cancers

Systemic therapy | Urinary systemWilm's tumour

Trial Overview Read MoreRead more

This phase II trial is evaluating how well combinations of chemotherapy (UH-3 and ICE/Cyclo/Tropo) work in treating children, adolescents and young adults with newly diagnosed stage II-IV diffuse anaplastic Wilm's Tumour (DAWT) or relapsed favourable histology Wilm's Tumour (FHWT).
 

This trial is treating patients with Wilm's tumour.

This is a systemic therapy trial.

You may be able to join this trial if:

  • You have been diagnosed with cancer, but have not received any treatment.
  • You have had treatment but your cancer has gotten worse or has not responded to the treatment you have been given.
  • You have had treatment, but your cancer has come back.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Treatment of Newly Diagnosed Diffuse Anaplastic Wilms Tumors (DAWT) and Relapsed Favorable Histology Wilms Tumors (FHWT)

Cooperative Group

Children's Oncology Group

Other Non-Commercial Sponsor

National Cancer Institute (NCI)

Summary

This is a non-randomised, open-label study investigating the effects of different regimens of chemotherapy in people with newly diagnosed stage II-IV diffuse anaplastic Wilm's tumours (DAWT) or relapsed favourable histology Wilm's Tumours (FHWT). Participants will DAWT and standard-risk relapsed FHWT will receive the UH-3 chemotherapy regimen, which includes vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan. Participants with high- and very-high risk FHWT will receive the ICE/Cyclo/Tropo chemotherapy regimen, which includes ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan. All treatments will be administered intravenously (via IV).

Recruiting Hospitals Read MoreRead more

Royal Childrens Hospital
Parkville
Trial Coordinator
CCC.ClinicalTrials@rch.org.au

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next